Joyce Steinberg

3.6k total citations · 3 hit papers
58 papers, 2.6k citations indexed

About

Joyce Steinberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Joyce Steinberg has authored 58 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Joyce Steinberg's work include Prostate Cancer Treatment and Research (21 papers), Cancer Treatment and Pharmacology (11 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Joyce Steinberg is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Cancer Treatment and Pharmacology (11 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Joyce Steinberg collaborates with scholars based in United States, Canada and Italy. Joyce Steinberg's co-authors include Philip J. Johnson, Winnie Yeo, Paul K.S. Chan, Nancy W.Y. Leung, John S. Tam, Sheng Zhong, Wing Ming Ho, Pun Hui, Benny Zee and Fred Saad and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Joyce Steinberg

57 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Tiffany A. Traina, Denise A. Yardley et al. Journal of Clinical Oncology profile →
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020 266 citations Cora N. Sternberg, Karim Fizazi et al. profile →
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 175 citations Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce Steinberg United States	21	980	884	694	611	534	58	2.6k
Gerrit DeBoer Canada	26	1.1k 1.1×	965 1.1×	477 0.7×	379 0.6×	352 0.7×	43	2.8k
Tiziana Camerini Italy	27	1.2k 1.3×	419 0.5×	928 1.3×	1.2k 2.0×	594 1.1×	39	3.5k
Austin G. Duffy United States	27	1.5k 1.5×	749 0.8×	589 0.8×	716 1.2×	472 0.9×	87	2.8k
Timothy L. Frankel United States	28	1.5k 1.5×	557 0.6×	358 0.5×	231 0.4×	407 0.8×	81	2.6k
Anneke J. van Vuuren Netherlands	30	1.4k 1.4×	899 1.0×	1.1k 1.6×	916 1.5×	196 0.4×	57	3.1k
Vincenza Conteduca Italy	38	1.2k 1.2×	2.1k 2.4×	372 0.5×	440 0.7×	1.1k 2.1×	151	3.8k
Osama E. Rahma United States	28	2.1k 2.2×	520 0.6×	371 0.5×	271 0.4×	310 0.6×	113	2.9k
Matthew M. Yeh United States	28	850 0.9×	385 0.4×	528 0.8×	921 1.5×	325 0.6×	83	2.4k
D. Voliotis Germany	20	953 1.0×	604 0.7×	543 0.8×	1.4k 2.2×	451 0.8×	48	3.0k
Svend Aage Engelholm Denmark	29	812 0.8×	985 1.1×	288 0.4×	242 0.4×	361 0.7×	94	3.3k

Countries citing papers authored by Joyce Steinberg

Since Specialization

Citations

This map shows the geographic impact of Joyce Steinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Steinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Steinberg more than expected).

Fields of papers citing papers by Joyce Steinberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Steinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Steinberg. The network helps show where Joyce Steinberg may publish in the future.

Co-authorship network of co-authors of Joyce Steinberg

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce Steinberg. A scholar is included among the top collaborators of Joyce Steinberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce Steinberg. Joyce Steinberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGregor, Bradley A., Peter H. O’Donnell, Arjun Vasant Balar, et al.. (2022). Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European Urology. 81(5). 515–522. 20 indexed citations

Giorgi, Ugo De, Maha Hussain, Neal D. Shore, et al.. (2021). Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer. 159. 237–246. 8 indexed citations

Yu, Evan Y., Daniel P. Petrylak, Peter H. O’Donnell, et al.. (2021). Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 22(6). 872–882. 175 indexed citations breakdown →

Heijden, Michiel S. van der, Shilpa Gupta, Matt D. Galsky, et al.. (2020). 798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer. Annals of Oncology. 31. S605–S606. 20 indexed citations

O’Donnell, Peter H., Matthew D. Galsky, Jonathan E. Rosenberg, et al.. (2020). 746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors. Annals of Oncology. 31. S579–S580. 10 indexed citations

Oza, Amit M., Stanley B. Kaye, Cristiana Sessa, et al.. (2018). Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic Oncology. 149(2). 275–282. 27 indexed citations

Schwartzberg, Lee S., Denise A. Yardley, Anthony Elias, et al.. (2017). A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research. 23(15). 4046–4054. 42 indexed citations

Papadopoulos, Kyriakos P., Javier López‐Jiménez, Scott E. Smith, et al.. (2016). A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma. 57(8). 1848–1855. 34 indexed citations

Schmid, Peter, Ahmad Awada, Hardeep Uppal, et al.. (2015). Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Annals of Oncology. 26. iii6–iii6. 14 indexed citations

10.

Clemens, Michael, Oleg Gladkov, Elaina M. Gartner, et al.. (2014). Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 171–179. 67 indexed citations

11.

Papadopoulos, Kyriakos P., Scott E. Smith, Joyce Steinberg, et al.. (2012). A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.. Blood. 120(21). 2731–2731. 4 indexed citations

12.

Soo, Ross A., Septian Hartono, Choon Hua Thng, et al.. (2009). Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. Journal of Clinical Oncology. 27(28). 4718–4726. 72 indexed citations

13.

Nelson, Joel B., Joseph L. Chin, Fred Saad, et al.. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer. Cancer. 113(9). 2478–2487. 190 indexed citations

14.

Yeo, Winnie, Paul K.S. Chan, Sheng Zhong, et al.. (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. Journal of Medical Virology. 62(3). 299–307. 496 indexed citations

15.

Yeo, Winnie, Joyce Steinberg, John S. Tam, et al.. (1999). Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. Journal of Medical Virology. 59(3). 263–269. 90 indexed citations

16.

Mok, Tony, Joyce Steinberg, Anthony T.�C. Chan, et al.. (1998). Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer. 82(12). 2439–2448. 19 indexed citations

17.

Steinberg, Joyce & Maureen Trudeau. (1993). Neutropenia Induced by Aminoglutethimide in Breast Cancer. Journal of the Royal Society of Medicine. 86(8). 480–481.

18.

Steinberg, Joyce, et al.. (1992). Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. European Journal of Cancer. 28(11). 1817–1820. 58 indexed citations

19.

Steinberg, Joyce & Pamela J. Goodwin. (1991). Alcohol and breast cancer risk — putting the current controversy into perspective. Breast Cancer Research and Treatment. 19(3). 221–231. 13 indexed citations

20.

Beall, Gildon, Fatima Morales, David T. Imagawa, et al.. (1990). A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients. AIDS. 4(7). 679–682. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact